JP7701734B2 - 抗ａベータワクチン療法 - Google Patents
抗ａベータワクチン療法 Download PDFInfo
- Publication number
- JP7701734B2 JP7701734B2 JP2021569155A JP2021569155A JP7701734B2 JP 7701734 B2 JP7701734 B2 JP 7701734B2 JP 2021569155 A JP2021569155 A JP 2021569155A JP 2021569155 A JP2021569155 A JP 2021569155A JP 7701734 B2 JP7701734 B2 JP 7701734B2
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- administered
- disease
- amyloid
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810.1 | 2019-05-21 | ||
| EP19175810 | 2019-05-21 | ||
| EP19185593.1 | 2019-07-10 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20171549.7 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| EP20172205.5 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533422A JP2022533422A (ja) | 2022-07-22 |
| JP2022533422A5 JP2022533422A5 (enExample) | 2023-05-29 |
| JP7701734B2 true JP7701734B2 (ja) | 2025-07-02 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569155A Active JP7701734B2 (ja) | 2019-05-21 | 2020-05-20 | 抗ａベータワクチン療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (enExample) |
| EP (1) | EP3972633A1 (enExample) |
| JP (1) | JP7701734B2 (enExample) |
| KR (1) | KR20220010552A (enExample) |
| CN (1) | CN113853214A (enExample) |
| AU (1) | AU2020277682A1 (enExample) |
| BR (1) | BR112021023209A2 (enExample) |
| CA (1) | CA3138145A1 (enExample) |
| CL (1) | CL2021003051A1 (enExample) |
| IL (1) | IL288252A (enExample) |
| MX (1) | MX2021014102A (enExample) |
| MY (1) | MY210394A (enExample) |
| SG (1) | SG11202112329RA (enExample) |
| TW (1) | TW202110425A (enExample) |
| WO (1) | WO2020234405A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
| KR20250137159A (ko) * | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014531455A (ja) | 2011-09-23 | 2014-11-27 | エーシー イミューン ソシエテ アノニム | ワクチン療法 |
| JP2021521149A (ja) | 2018-04-10 | 2021-08-26 | エイシー イミューン ソシエテ アノニム | 抗−ａベータ治療用ワクチン |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014531455A (ja) | 2011-09-23 | 2014-11-27 | エーシー イミューン ソシエテ アノニム | ワクチン療法 |
| JP2021521149A (ja) | 2018-04-10 | 2021-08-26 | エイシー イミューン ソシエテ アノニム | 抗−ａベータ治療用ワクチン |
Non-Patent Citations (1)
| Title |
|---|
| PLOS ONE，2016年，Vol. 11, No.3, e0152471 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020234405A1 (en) | 2020-11-26 |
| CA3138145A1 (en) | 2020-11-26 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (en) | 2022-03-30 |
| JP2022533422A (ja) | 2022-07-22 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| SG11202112329RA (en) | 2021-12-30 |
| BR112021023209A2 (pt) | 2022-01-18 |
| MX2021014102A (es) | 2022-02-11 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| MY210394A (en) | 2025-09-18 |
| IL288252A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Monsonego et al. | Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease | |
| Zhang et al. | Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients | |
| TWI508975B (zh) | 單株抗體 | |
| Fiala et al. | Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients | |
| JP5889529B2 (ja) | アミロイド原性疾患の処置 | |
| Agardh et al. | Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes | |
| JP7701734B2 (ja) | 抗ａベータワクチン療法 | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| KR20030066695A (ko) | 베타 아밀로이드 펩티드를 인식하는 인간화된 항체 | |
| RU2011144307A (ru) | Фармацевтическая композиция | |
| US20080248055A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| Gandy et al. | Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-β vaccination in nonhuman primates | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| Shao et al. | Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis | |
| HK40058406A (en) | Anti-abeta vaccine therapy | |
| EA049756B1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| US20080226668A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| US20050250691A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| JP2026503655A (ja) | 抗Ａβワクチン療法 | |
| US20100119555A1 (en) | Methods and Compositions for the Treatment and Diagnosis of Cancer | |
| US20250049900A1 (en) | Method of safe administration of tau phosphopeptide conjugate | |
| Khachanova et al. | Extending the potential of the treatment of multiple sclerosis with a new agent for oral use–teriflunomide (Aubagio) | |
| Hoffmann | Early neurodegenerative changes in a rat model of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230519 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240514 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241126 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250526 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250603 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250613 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7701734 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |